Cardiff Oncology, Inc. (CRDF) vs Inovio Pharmaceuticals, Inc. (INO)
A side-by-side comparison of Cardiff Oncology, Inc. and Inovio Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRDF
Cardiff Oncology, Inc.
$1.08HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
INO
Inovio Pharmaceuticals, Inc.
$1.15HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — CRDF vs INO
growth of $100 · dividends reinvested · last 10yCRDF -99.6% (-43.1%/yr)INO -99.0% (-36.9%/yr)INO compounded faster over this window
CRDF INO
CRDF vs INO: by the numbers
- •CRDF is the larger company ($83M vs $79M market cap).
- •Both run net losses; CRDF's is the smaller (-7884.06% vs -130000.00% net margin).
Metrics side by side
Valuation
| Metric | CRDF | INO |
|---|---|---|
| P/S ratio | 163.10 | N/A |
| P/B ratio | 3.12 | 18.13 |
Profitability
| Metric | CRDF | INO |
|---|---|---|
| Gross margin | 100.00% | 100.00% |
| Operating margin | -8256.32% | -132871.32% |
| Net margin | -7884.06% | -130000.00% |
| ROE | -150.95% | -1542.57% |
| ROIC | -159.30% | -836.58% |
Growth (annualized)
| Metric | CRDF | INO |
|---|---|---|
| Revenue CAGR (5Y) | 5.15% | N/A |
| Total return CAGR (5Y) | -30.36% | -57.05% |
Frequently asked
- How have CRDF and INO total returns compared?
- Over the past 10 years, CRDF delivered -43.20% and INO delivered -36.78% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.